FDA approves Orzeyful as first treatment to address the full range of narcolepsy type 1 symptoms
- nuaxia
- Aug 6
- 2 min read
The orexin receptor agonist provides adults with a treatment that targets the underlying loss of orexin signalling rather than managing individual symptoms separately.
The US Food and Drug Administration (FDA) has approved Orzeyful (oveporexton) for the treatment of adults with narcolepsy type 1, making it the first medicine approved to address the condition as a complete disorder by restoring orexin signalling.
The approval introduces a new therapeutic approach for patients experiencing excessive daytime sleepiness, cataplexy and other symptoms, although commercial launch must await scheduling by the US Drug Enforcement Administration (DEA).
Field | Content |
Alert Type | Drug Approval |
Drug Name | Orzeyful (oveporexton) |
Indication | Treatment of narcolepsy type 1 in adults. |
Therapy Area(s) | Neurology; Sleep Medicine |
Geography | United States (FDA) |
What Happened | On 5 August 2026, the FDA approved Orzeyful (oveporexton) for the treatment of adults with narcolepsy type 1. The twice-daily oral therapy is the first approved medicine to directly activate the orexin receptor and treat the disorder by addressing the underlying loss of orexin signalling rather than targeting individual symptoms. Marketing cannot begin until the DEA completes scheduling under the Controlled Substances Act. |
Why It Matters | Existing treatments generally focus on individual symptoms such as excessive daytime sleepiness or cataplexy. Orzeyful introduces a disease-targeted approach that demonstrated improvements across multiple symptoms of narcolepsy type 1, providing clinicians with a new treatment option that addresses the condition more broadly. |
Supporting Context | Narcolepsy type 1 is caused by the loss of orexin-producing neurons, leading to excessive daytime sleepiness, cataplexy, sleep paralysis, hallucinations and disrupted night-time sleep. FDA approval was supported by two Phase III clinical trials involving 273 adults with narcolepsy type 1. |
Key Takeaway | FDA approval makes Orzeyful the first therapy to target the underlying orexin deficiency responsible for narcolepsy type 1 while addressing the full spectrum of the condition's symptoms. |
What to Watch | The DEA's scheduling decision will determine when Orzeyful becomes commercially available in the United States, followed by reimbursement decisions and clinical adoption. |
Primary Source | |
Relevant Date | 5 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments